89 related articles for article (PubMed ID: 8608043)
41. Financial costs, benefits, and patient risk preferences in node-negative breast cancer: insights from a decision analysis model.
Hillner BE
Recent Results Cancer Res; 1993; 127():277-84. PubMed ID: 8502826
[No Abstract] [Full Text] [Related]
42. Using cost-effectiveness analysis to define a breast cancer benefits package for the uninsured.
Malin JL; Keeler E; Wang C; Brook R
Breast Cancer Res Treat; 2002 Jul; 74(2):143-53. PubMed ID: 12186375
[TBL] [Abstract][Full Text] [Related]
43. Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study.
Cariou A; Rouzier R; Baffert S; Soilly AL; Hequet D
PLoS One; 2018; 13(8):e0202385. PubMed ID: 30138470
[TBL] [Abstract][Full Text] [Related]
44. Long-term toxicity and economic aspects: critical review.
Brunner KW
Recent Results Cancer Res; 1993; 127():285-7. PubMed ID: 8502827
[No Abstract] [Full Text] [Related]
45. Comment: adjuvant therapy decisions in node-negative breast cancer.
Anand A; Anand N; Anand A
Ann Pharmacother; 1995 Sep; 29(9):940-1. PubMed ID: 8547753
[No Abstract] [Full Text] [Related]
46. Clinical decision making vs programme evaluation perspectives.
Levine MN; Gafni A
Pharmacoeconomics; 1993 Sep; 4(3):228-31. PubMed ID: 10147132
[No Abstract] [Full Text] [Related]
47. Breast cancer: clinical decision making.
Hayes JD; Clark EJ
Pharmacoeconomics; 1993 Sep; 4(3):226-8. PubMed ID: 10147131
[No Abstract] [Full Text] [Related]
48. The Efficacy of Software to Help Patients Understand Drug for Adjuvant Treatment for Breast Cancer: A Pilot Randomized Controlled Trial.
Kuba S; Yamanouchi K; Morita M; Sakimura C; Inamasu E; Hatachi T; Otsubo R; Matsumoto M; Yano H; Miyamoto J; Sato S; Nakagawa H; Kanetaka K; Takatsuki M; Nagayasu T; Eguchi S
Acta Med Okayama; 2020 Apr; 74(2):95-101. PubMed ID: 32341582
[TBL] [Abstract][Full Text] [Related]
49. Quality of life assessment in the International Breast Cancer Study Group: past, present, and future.
Hürny C; Bernhard J; Coates A
Recent Results Cancer Res; 1998; 152():390-5. PubMed ID: 9928574
[TBL] [Abstract][Full Text] [Related]
50. Economic evaluation of alternative adjuvant chemotherapy modalities for colorectal carcinoma.
Tierney WM; Fendrick AM
J Clin Gastroenterol; 1996 Dec; 23(4):248-50. PubMed ID: 8957724
[TBL] [Abstract][Full Text] [Related]
51. Assessment of quality of life and benefits from adjuvant therapies in breast cancer.
Aaronson NK
Recent Results Cancer Res; 1993; 127():201-10. PubMed ID: 8502817
[No Abstract] [Full Text] [Related]
52. Adjuvant systematic therapy and survival after breast cancer.
Evans RA
N Engl J Med; 1994 Aug; 331(6):403; author reply 403-4. PubMed ID: 8028630
[No Abstract] [Full Text] [Related]
53. Effects of adjuvant systemic treatments in breast cancer.
Valagussa P; Bonadonna G
Ann Oncol; 1996 Mar; 7(3):221-2. PubMed ID: 8740782
[No Abstract] [Full Text] [Related]
54. Meeting report: Breast cancer in the older woman.
Martoni A; Cucinotta D; Balducci L
Tumori; 2004; 90(4):437-45. PubMed ID: 15510992
[No Abstract] [Full Text] [Related]
55. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
Reed SD; Lyman GH
Cancer; 2012 Dec; 118(24):6298-9; author reply 6299-300. PubMed ID: 22674145
[No Abstract] [Full Text] [Related]
56. Evaluating quality and quantity of life in breast cancer adjuvant trials.
Fetting JH
J Clin Oncol; 1988 Dec; 6(12):1795-7. PubMed ID: 3058873
[No Abstract] [Full Text] [Related]
57. Survival gain in cost-effectiveness studies.
Trippoli S; Vaiani M; Messori A; Tendi E
J Clin Oncol; 2000 Sep; 18(18):3318. PubMed ID: 10986065
[No Abstract] [Full Text] [Related]
58. Quality of life: philosophical question or clinical reality?
Slevin ML
BMJ; 1992 Aug; 305(6851):466-9. PubMed ID: 1392964
[No Abstract] [Full Text] [Related]
59. Avoiding overuse of adjuvant therapies.
Romero D
Nat Rev Clin Oncol; 2018 Aug; 15(8):469. PubMed ID: 29921846
[No Abstract] [Full Text] [Related]
60. Do we need a "stopping rule" for breast cancer?
Hudis CA
Cancer Invest; 1994; 12(5):543-4. PubMed ID: 7922711
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
